Gotowa bibliografia na temat „HIV”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „HIV”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "HIV"
Troisi, CL, FB Hollinger, WK Hoots, C. Contant, J. Gill, M. Ragni, R. Parmley, C. Sexauer, E. Gomperts i G. Buchanan. "A multicenter study of viral hepatitis in a United States hemophilic population". Blood 81, nr 2 (15.01.1993): 412–18. http://dx.doi.org/10.1182/blood.v81.2.412.412.
Pełny tekst źródłaTroisi, CL, FB Hollinger, WK Hoots, C. Contant, J. Gill, M. Ragni, R. Parmley, C. Sexauer, E. Gomperts i G. Buchanan. "A multicenter study of viral hepatitis in a United States hemophilic population". Blood 81, nr 2 (15.01.1993): 412–18. http://dx.doi.org/10.1182/blood.v81.2.412.bloodjournal812412.
Pełny tekst źródłaTserashkou, D. V., V. M. Mitsura, E. V. Voropaev i O. V. Osipkina. "VIRAL COINFECTIONS IN PATIENTS WITH CHRONIC HEPATITIS B: THEIR PREVALENCE AND CLINICAL SIGNIFICANCE". Hepatology and Gastroenterology 4, nr 2 (2020): 171–76. http://dx.doi.org/10.25298/2616-5546-2020-4-2-171-176.
Pełny tekst źródłaPrasetyo, Afiono Agung, Paramasari Dirgahayu, Yulia Sari, Hudiyono Hudiyono i Seiji Kageyama. "Molecular epidemiology of HIV, HBV, HCV, and HTLV-1/2 in drug abuser inmates in central Javan prisons, Indonesia". Journal of Infection in Developing Countries 7, nr 06 (15.06.2013): 453–67. http://dx.doi.org/10.3855/jidc.2965.
Pełny tekst źródłaDickson-Spillmann, Maria, Severin Haug, Ambros Uchtenhagen, Philip Bruggmann i Michael P. Schaub. "Rates of HIV and Hepatitis Infections in Clients Entering Heroin-Assisted Treatment between 2003 and 2013 and Risk Factors for Hepatitis C Infection". European Addiction Research 22, nr 4 (11.12.2015): 181–91. http://dx.doi.org/10.1159/000441973.
Pełny tekst źródłaKartashov, Mikhail Yu, Kirill A. Svirin, Ekaterina I. Krivosheina, Elena V. Chub, Vladimir A. Ternovoi i Galina V. Kochneva. "Prevalence and molecular genetic characteristics of parenteral hepatitis B, C and D viruses in HIV positive persons in the Novosibirsk region". Problems of Virology 67, nr 5 (19.11.2022): 423–38. http://dx.doi.org/10.36233/0507-4088-133.
Pełny tekst źródłaBasimane-Bisimwa, Parvine, Giscard Wilfried Koyaweda, Edgarthe Ngaïganam, Ulrich Vickos, Ornella Anne Demi Sibiro, Brice Martial Yambiyo, Benjamin Seydou Sombié i in. "Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic". PLOS ONE 19, nr 5 (9.05.2024): e0291155. http://dx.doi.org/10.1371/journal.pone.0291155.
Pełny tekst źródłaZiaee, Masood, Roghiya Azizee i Mohammad Hasan Namaei. "Prevalence of HCV Infection in Hemodialysis Patients of South Khorasan in Comparison With HBV, HDV, HTLV I/II, And HIV Infection". Bangladesh Journal of Medical Science 13, nr 1 (24.12.2013): 36–39. http://dx.doi.org/10.3329/bjms.v13i1.13903.
Pełny tekst źródłaSarmento, Vânia Pinto, Alex Junior Souza de Souza, Marcella Katheryne Marques Bernal, André Antônio Correa das Chagas, Andreza Pinheiro Malheiros, Dickson Ciro Nascimento de Brito, Sandra Souza Lima i Heloisa Marceliano Nunes. "Hepatites B e C entre portadores de HIV na Amazônia oriental brasileira, 2015-2016: prevalência, epidemiologia e características moleculares do HBV e HCV". CONTRIBUCIONES A LAS CIENCIAS SOCIALES 17, nr 3 (27.03.2024): e5026. http://dx.doi.org/10.55905/revconv.17n.3-309.
Pełny tekst źródłaCrobu, Maria Grazia, Paolo Ravanini, Clotilde Impaloni, Claudia Martello, Olivia Bargiacchi, Christian Di Domenico, Giulia Faolotto i in. "Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection". Viruses 16, nr 6 (20.06.2024): 992. http://dx.doi.org/10.3390/v16060992.
Pełny tekst źródłaRozprawy doktorskie na temat "HIV"
Soares, Sampaio Aletheia. "Marcadores sorológicos para os vírus da hepatite B e C em pacientes HIV-positivos atendidos no Hospital Universitário Oswaldo Cruz". Universidade Federal de Pernambuco, 2005. https://repositorio.ufpe.br/handle/123456789/7445.
Pełny tekst źródłaA ocorrência de co-infecção pelo HIV e hepatites B e C tem sido relatada desde a era- HAART (do inglês Highly Active Antinetrovial Therapy), quando a mortalidade nas pessoas infectadas pelo HIV começou diminuir. Como conseqüência do fato de terem as mesmas rotas de transmissão, a co-infecção do HBV ou HCV em pessoas infectadas pelo HIV tem aumentado e tornou-se um problema de saúde pública. No Brasil, a prevalência média da coinfecção HIV e hepatites, encontrada pelo Ministério da Saúde é em torno de 40%, com a maioria em grupos de usuários de drogas. Freqüências variáveis de co-infecção têm sido relatadas, dependendo da população e da região estudada. O objetivo principal deste estudo foi identificar a freqüência de marcadores sorológicos para hepatite B e C em pacientes infectados pelo HIV, acompanhados em um hospital escola e os possíveis fatores associados à presença de tais marcadores. Quatrocentos e vinte e nove pacientes foram estudados, de ambos os sexos e com idade variando entre 18 a 77 anos. Os participantes respondiam um questionário específico, com características sócio-demográficas e tinham uma amostra de sangue testada para os marcadores HBsAg, Anti-HBc total e Anti-HCV, utilizando a técnica MEIA-Axym-Abbott. A freqüência encontrada de marcadores foi 10,3% para o HBsAg, 38,7% para o Anti-HBc total e 10,7% para o Anti-HCV. Dentre os pacientes, 1,4% possuíam tanto HBsAg quanto Anti-HCV positivos. Não houve associação significante estatisticamente entre as variáveis parceiro homossexual, uso de drogas endovenosas, ingesta de álcool, tatuagem ou piercing, cirurgia, procedimentos invasivos e hemotransfusão e a infecção pelo HBV, expressa pela positividade do HBsAg. A única variável que mostrou associação com infecção pelo HBV foi uso de drogas inalatórias. Nenhuma destas variáveis, incluindo, parceiro homossexual, uso de drogas endovenosas, uso de drogas inalatórias, ingesta de álcool, tatuagem ou piercing, cirurgia, procedimentos invasivos e hemotransfusão tiveram associação significativa estatisticamente com a presença do Anti-HCV. Este estudo encontrou freqüências comparáveis com outros relatados no Brasil, mas com freqüências de coinfeccção menores que aqueles das regiões Sul e Sudeste. Entretanto, nenhuma associação específica com comportamentos de risco foi encontrada neste estudo, mostrando importante diferença quando comparado com estudos realizados em outras regiões do Brasil
RUSSO, DARIO. "Diagnosi parallela automatizzata di infezioni virali trasmissibili per via ematica (HIV, HCV, HBV)". Doctoral thesis, Università degli Studi di Milano, 2007. http://hdl.handle.net/2434/33618.
Pełny tekst źródłaSouza, Iury Oliveira. "Validação de ensaio imunocromatográfico para a detecção múltipla de anticorpos específicos contra HIV, HBV e HCV". reponame:Repositório Institucional da UFBA, 2013. http://www.repositorio.ufba.br/ri/handle/ri/11787.
Pełny tekst źródłaMade available in DSpace on 2013-06-10T18:28:37Z (GMT). No. of bitstreams: 1 Dissertação_ICS_Iury Souza.pdf: 1047267 bytes, checksum: 06bc8acdb629b7e8ae63feab201995ad (MD5)
CAPES
Cerca de 33,3 milhões de pessoas apresentam infecção pelo Human Immunodeficiency Virus (HIV) no mundo; 180 milhões estão infectados pelo Hepatitis C Virus HCV e estima-se que 360 milhões apresentem infecção ativa pelo Hepatitis B Virus (HBV). Outra realidade mundial é a co-infecção entre esses vírus. Os dados mostram a importância global dessas viroses e a urgência do desenvolvimento de novos ensaios de diagnóstico sensíveis, específicos, rápidos e de baixo custo, que possam atender à demanda de entidades públicas inseridas em programas para prevenção e diagnostico dessas doenças. O presente trabalho consiste em validação relativa de um novo teste imunocromatográfico desenvolvido pela empresa canadense Medmira para detecção de anticorpos específicos contra HIV, HCV e HBV. Os resultados encontrados foram extremamente favoráveis para a detecção de anticorpos específicos para HIV, apresentando 98,6% de sensibilidade e 100% de especificidade. Para o anti-HBV a sensibilidade e especificidade encontradas foram de 90,0% e 98,6%, e de 86,3% e 100%, para anti-HCV, respectivamente. Nenhuma reatividade cruzada foi encontrada e a reprodutibilidade e repetitividade foram de 100%. O índice kappa e a acurácia global do teste foram de 0,91 (0,88-0,94) e 95,5% (93,5-97,5), respectivamente. Conclui-se que o ensaio imunocromatográfico é clinicamente útil em triagens rápidas para detecção de anticorpos anti-HIV, HCV e HBV.
Salvador
Duvall, Melody Gayle. "HIV-specific cellular immune responses in HIV-1 and HIV-2 infection". Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.441307.
Pełny tekst źródłaLindström, Anna. "Resistance to antiviral drugs in HIV and HBV /". Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-239-X/.
Pełny tekst źródłaCosta, Cintia Bezerra Almeida. "Polimorfismo do HLA-G na coinfecção HIV/HCV". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/22/22132/tde-21052014-181750/.
Pełny tekst źródłaThe general objective of the research was to associate the polymorphism of the gene HLA-G (region 3\' NT) with the co-infection HIV/HCV and with the groups (HIV, HCV and healthy control). It is a cross-sectional, comparative, descriptive study. 560 individuals participated of the study, being 156 healthy control individuals, 102 co- infected HIV/HCV, 186 infected by HIV and 116 by HCV. For identifying the polymorphisms, the genomic DNA was extracted from the total blood and the genotyping was made by PCR and visualized in gel of polyacrylamide at 7%, in which the polymorphism of 14pb was identified, and by sequencing the other seven SNPs. The social demographic results point that the most of the sample was composed by male adult individuals. Regarding the color of the skin, in the comparison between the groups HCV and HIV/HCV, a bigger number of co-infected with black skin and brown-skinned was observed than in the mono infected (P=0,0001). Regarding to the category of exposition for acquisition of the HIV, in the comparison between the groups HIV and HIV/HCV, a significant difference was observed in the transmission through heterosexual exposition, being its frequency bigger in the group HIV (P=0,0000). In the case of the comparison between the groups HCV and HIV/HCV, the difference in the heterosexual transmission was also observed, being its frequency significantly higher in the group HIV/HCV (P=0,0001). About the finding related to the genotype of the HCV, in the comparison between the groups HCV and HIV/HCV, the genotype 1a presented higher frequency in the co- infected (P=0,0001). Regarding to the viral load of the HIV, in the comparison between the groups HIV and HIV/HCV, the group of the mono infection presented bigger viral load that the group of the co-infection (P=0,0350). Regarding to the level of hepatic fibrosis, in the comparison between the groups HCV and HIV/HCV, the group of co-infection has a lighter fibrosis that the group of the mono infection (P=0,0009). Regarding to the genetic polymorphisms of the region 3\' NT of the HLA-G, it was found that the genotype of heterozygosis Del/Ins of 14 pb, presented significant difference in the individuals co-infected by the HIV/HCV (P=0,0216) when compared with the control group. About the SNP +3003, the comparison of the groups HCV and healthy control, it was showed that the allele +3003T presented a significant higher frequency in the group HCV (P=0,0147); the genotype +3003C/T presented a higher frequency in the control group (P=0,0095); the genotype +3003T/T was bigger in the group HCV (P=0,0095). The comparison between the groups HIV and HCV showed that the frequency of the allele +3003C was bigger in the group HIV (P=0,0463); and the genotype +3003T/T presented a bigger frequency in the group (P=0,0494). The frequency of the genotype +3187A/A was bigger in the group HIV/HCV in comparison to the HIV (P=0,0193); and of the +3187A/G was bigger in the group HIV (P=0,0187). The genotype +3196C/G presented frequency significantly bigger in the group HIV than in the healthy control (P=0,0213). The UTR-10, in comparison between the groups HIV and control, showed bigger frequency in the group HIV (P=0,0044); when compared the groups HIV/HCV and HIV, frequency was bigger in the group HIV (P=0,0300) and in the comparison between the groups HIV and HCV, its frequency was also bigger in the group (P=0,0140). The UTR-4, in the comparison of the groups HCV and healthy control, revealed a bigger frequency in the control group (P=0,0147). The UTR-9, in comparison of the groups HIV/HCV and HIV, showed bigger frequency in the group HIV/HCV (P=0,0460). Regarding to the clinical data, the presence of the allele T in the position +3035, was significantly associated to bigger viral load of the HCV, above 400.000 copies /mL (P=0,0244). About the types of genotypes of the HCV, the presence of the allele +3027C was associated with the subtype 1a of the HCV (P=0,0109). Additionally, the presence of the genotype C/C in the position +3027 was also significantly associated with the subtype 1a of the HCV (P=0,0015). Still, the allele A of the SNP +3187 was significantly associated with the other genotypes of the HCV, excluding the 1a (P=0,0369). Although the function of the gene HLA-G, is not totally clarified, studies have been developed for better elucidate its function in the physiological contexts, like gestation, and pathological, such as tumours, transplants, infectious and inflammatory diseases. These studies aim to extend the knowledge about the immunological system and contribute for the development of new diagnostic and therapeutic strategies. The results of this study contribute for enhancement of the knowledge about the polymorphisms of the region 3\' NT of the gene HLA-G, in the co-infection HIV/HCV. As well as, in the improvement of the assistance of nursing that must seek reducing the morbid mortality by the pathology referred. However, there is still a long path to be followed in the comprehension of the immunogenic factors involved in the co-infection by the HIV/HCV
Uccellini, L. "HOST GENETIC INFLUENCE ON HIV AND HCV INFECTIONS". Doctoral thesis, Università degli Studi di Milano, 2013. http://hdl.handle.net/2434/215587.
Pełny tekst źródłaFontes, Adriele Souza. "Resposta específica aos antígenos da vacina anti-HPV em homens infectados pelo HIV-1". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/99/99131/tde-03082015-103315/.
Pełny tekst źródłaIntroduction: Infection with Human Papilloma Virus (HPV) has been reported as one of the sexually transmitted diseases with a higher incidence nowadys, but its prevalence must be clarified in men, mainly due to low presence of symptoms. Moreover, few studies have been performed in this population until now to verify the immune response post-vaccination. The hypothesis here suggested will be the key for better understanding of the immunopathogenesis, the vaccine´s response in HIV-infected patients and collaborate in the design and strategies of vaccination against HPV in HIV-infected population. Objectives: Analyze the specific response to antigens of HPV vaccine in HIV-infected men. Methods: A total of 24 HIV-infected patients who were in accordance with the inclusion criteria during the data collection period were vaccinated with anti-HPV bivalent vaccine in three period doses: zero, two and six months. The groups were distributed in: Control group (five healthy subjects with negative serology against HIV); Group A (nine subjects with CD4 <500 cells/mm³; Group B (10 subjects with CD4 >500 cells/mm³). ELISA was performed to detect the level of antibodies anti-HPV before and after vaccination in the studied cohort. Postenarly, cells of these groups were submitted in culture to verify citokynes production (IFN?, IL17, TNF, IL6 and IL10) using CBA methodology. Results: We obtained seroconversion after the first dose of anti-HPV vaccine: control group 60%, group A 55,6% and group B 30%. In the second dose: control group 80%, group A 88,8% and Group B 80%. And at last, the third dose: Control Group 100%, Group A 88,8% and group B 90%. IL 6 citokyne (TH2 response) was detected in higher level when compared Control, A and B groups (p<0.001). IFN? citokyne (TH1 response) was detect in low level only after the third dose of vaccination, showing relevance between A and B groups (p<0.0006). Additionally, higher IFN? production was detected when compared the control with A and B groups (p<0.001). Conclusion: HIV patients and controls (HIV-) were responders to anti-HPV vaccination. It was clear that an elevated cytokine production was detected between groups, suggesting immunomodulation of HIV + group. This work suggests relevant information that challenge: new studies in this population, verification of cross-reactions of the vaccine resulting in protection of other HPV types not present in this vaccine, and analyze for longer period the titers of anti-HPV antibodies in these patients. All together, our data can corroborate for vaccination in this population, thus decreasing the risk of infection, mortality and morbidity of the disease caused by HPV in men.
Ekman, Evelina, i Nicole Karlsson. "Upplevelser av vårdpersonalens bemötande gentemot patienter som lever med HIV, HBV eller HCV : En litteraturstudie". Thesis, Karlstads universitet, Fakulteten för hälsa, natur- och teknikvetenskap (from 2013), 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-83910.
Pełny tekst źródłaPantelic, Marija. "HIV, blame and shame : internalised HIV stigma among South African adolescents living with HIV". Thesis, University of Oxford, 2017. https://ora.ox.ac.uk/objects/uuid:ebc47dd0-df36-4b12-93b5-4e7d43603490.
Pełny tekst źródłaKsiążki na temat "HIV"
Sax, Paul E., Calvin J. Cohen i Daniel R. Kuritzkes. HIV essentials. Wyd. 5. Burlington, MA: Jones & Bartlett Learning, 2012.
Znajdź pełny tekst źródłaE, Sax Paul, Cohen Calvin J i Kuritzkes Daniel R, red. HIV essentials. Wyd. 2. Sudbury, Mass: Physicians' Press, 2008.
Znajdź pełny tekst źródłaCarter, Michael. Living with HIV. London: NAM, 2004.
Znajdź pełny tekst źródłaNye, K. E. HIV and AIDS. Oxford, UK: Bios Scientific Publishers, 1994.
Znajdź pełny tekst źródłaHoward, Libman, Makadon Harvey J. 1947- i American College of Physicians, red. HIV. Wyd. 3. Philadelphia: American College of Physicians, 2007.
Znajdź pełny tekst źródłaR, Prasad Vinayaka, i Kalpana Ganjam V, red. HIV protocols. Wyd. 2. New York, N.Y: Humana Press, 2008.
Znajdź pełny tekst źródłaR, Prasad Vinayaka, i Kalpana Ganjam V, red. HIV protocols. Wyd. 2. New York, N.Y: Humana Press, 2008.
Znajdź pełny tekst źródłaPrasad, Vinayaka R. HIV protocols. Wyd. 2. New York, N.Y: Humana Press, 2008.
Znajdź pełny tekst źródłaPrasad, Vinayaka R. HIV protocols. Wyd. 2. New York, N.Y: Humana Press, 2008.
Znajdź pełny tekst źródłaRepository, Indian HIV. Indian HIV Repository. Pune: National AIDS Research Institute, Indian Council of Medical Research, 2003.
Znajdź pełny tekst źródłaCzęści książek na temat "HIV"
Vachon, Marie-Louise C., Alicia C. Stivala i Douglas T. Dieterich. "HIV/HCV and HIV/HBV Co-infections". W Mount Sinai Expert Guides: Hepatology, 78–95. Oxford, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118748626.ch7.
Pełny tekst źródłaHu, Jianming, Kuancheng Liu i Jun Luo. "HIV–HBV and HIV–HCV Coinfection and Liver Cancer Development". W Cancer Treatment and Research, 231–50. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-03502-0_9.
Pełny tekst źródłaHu, Jianming, i Laurie Ludgate. "HIV–HBV and HIV–HCV Coinfection and Liver Cancer Development". W Cancer Treatment and Research, 241–52. Boston, MA: Springer US, 2007. http://dx.doi.org/10.1007/978-0-387-46816-7_9.
Pełny tekst źródłaPereira, Luis F., John J. Faragon, Antoine Douaihy i Courtney E. Kandler. "Treatment of Comorbid HIV/HCV". W HIV Psychiatry, 477–97. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-80665-1_18.
Pełny tekst źródłaCoffin, Carla S., i Norah A. Terrault. "Treatment of HCV, HDV, or HIV Coinfection". W Hepatitis B Virus and Liver Disease, 239–62. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-4843-2_13.
Pełny tekst źródłaZhou, Kali, i Norah A. Terrault. "Treatment of HCV, HDV, or HIV Coinfections". W Hepatitis B Virus and Liver Disease, 339–73. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-3615-8_15.
Pełny tekst źródłaHarr, Jeffrey N., Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan i in. "HIV". W Encyclopedia of Intensive Care Medicine, 1121. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_3145.
Pełny tekst źródłaBrooks, Richard B. "HIV". W Perioperative Medicine, 295–301. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-498-2_25.
Pełny tekst źródłaKiure, Annamaria, i Wafaie Fawzi. "HIV". W Handbook of Nutrition and Immunity, 303–37. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-790-1_14.
Pełny tekst źródłaGastpar, Markus, Werner Heinz, Thomas Poehlke i Peter Raschke. "HIV". W Glossar: Substitutionstherapie bei Drogenabhängigkeit, 71–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-662-07502-9_45.
Pełny tekst źródłaStreszczenia konferencji na temat "HIV"
Schmidbauer, C., D. Chromy, V. Schmidbauer, T. Bucsics, P. Schwabl, M. Mandorfer, B. Scheiner i in. "Epidemiological trends of HBV and HDV coinfection among HIV+ patients". W 51. Jahrestagung & 29. Fortbildungskurs der Österreichischen Gesellschaft für Gastroenterologie & Hepatologie (ÖGGH). Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1654658.
Pełny tekst źródłaDarvishian, Maryam, Carmine Rossi, Stanley Wong, Amanda Yu, Jason Wong, Jane Buxton, Mark Gilbert i in. "P386 Cancer risk among people with HIV, HBV and/or HCV infections". W Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.481.
Pełny tekst źródłaMartins de Matos Navarro Guia, Miguel Filipe, Micaela Caixeiro, José Pedro Boléo-Tomé, Patrícia Pacheco i Fernando Rodrigues. "Hospitalized tuberculosis: HIV versus non-HIV patients". W ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2995.
Pełny tekst źródłaLarsen, Teresa, David Goodsell, Dru Clark i Ernest Stewart. "Modeling HIV". W ACM SIGGRAPH 99 Conference abstracts and applications. New York, New York, USA: ACM Press, 1999. http://dx.doi.org/10.1145/311625.312156.
Pełny tekst źródłaConte, Fernanda Lopes, Amanda Alencar Cabral Morais, Nivea Orem de Oliveira Guedes, Mariana Villares Martins i Álisson Bigolin. "Análise do impacto da ampliação da Rede Nacional de Quantificação da Carga Viral do HIV, HBV e HCV point-of-care no Sistema Único de Saúde". W XIV Congresso da Sociedade Brasileira de DST - X Congresso Brasileiro de AIDS - V Congresso Latino Americano IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/dst-2177-8264-202335s1188.
Pełny tekst źródłaAkgun, Kathleen M., Margaret A. Pisani, Adeel A. Butt, Cynthia L. Gibert, Maria C. Rodriguez-Barradas, Amy C. Justice, David Rimland i Kristina A. Crothers. "Incidence And Mortality Of MICU Admission In HIV Infected (HIV+) And Non-Infected (HIV-) Veterans". W American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5200.
Pełny tekst źródłaRocha, Daniele, Elisabete Andrade, Marcela Fontana, Marisa Ribeiro, Elaine Motta, Daniela Godoy, Antonio Ferreira, Rodrigo Brindeiro, Amilcar Tanuri i Patricia Alvarez. "Desenvolvimento de uma nova partícula calibradora para o Kit NAT HIV/HCV/HBV Bio-Manguinhos". W III Seminário Anual Científico e Tecnológico de Bio-Manguinhos. Instituto de Tecnologia em Imunobiológicos, 2016. http://dx.doi.org/10.35259/isi.sact.2016_27367.
Pełny tekst źródłaStewart, J. M., C. Budhathoki, D. Bellinger i J. B. Hamilton. "P4.50 Associations of hiv testing with hiv stigma: implications for faith based hiv testing and treatment". W STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.547.
Pełny tekst źródłaLINDBERG, ALF A., i MICHEL KLEIN. "THERAPEUTIC HIV VACCINES". W Proceedings of the International Seminar on Nuclear War and Planetary Emergencies — 26th Session. WORLD SCIENTIFIC, 2002. http://dx.doi.org/10.1142/9789812776945_0006.
Pełny tekst źródłaSardi, Alejandro H., Juan Cadavid i Glenn Eiger. "HIV And Sarcoidosis". W American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a6662.
Pełny tekst źródłaRaporty organizacyjne na temat "HIV"
Pinter, Abraham. HIV Vaccines Based on Novel MULV-HIV Fusion Proteins. Fort Belvoir, VA: Defense Technical Information Center, lipiec 1999. http://dx.doi.org/10.21236/ada373677.
Pełny tekst źródłaBingamon, Brian Michael. HIV Mosaic Vaccine. Office of Scientific and Technical Information (OSTI), grudzień 2019. http://dx.doi.org/10.2172/1581247.
Pełny tekst źródłaKanki, Phyllis. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, lipiec 1999. http://dx.doi.org/10.21236/ada367779.
Pełny tekst źródłaKanki, Phyllis. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, lipiec 1997. http://dx.doi.org/10.21236/ada329299.
Pełny tekst źródłaKanki, Phyllis J. Interactions of HIV-1 and HIV-2 in West Africa. Fort Belvoir, VA: Defense Technical Information Center, październik 2002. http://dx.doi.org/10.21236/ada416999.
Pełny tekst źródłaSood, Neeraj, i Yanyu Wu. The Impact of Insurance and HIV Treatment Technology on HIV Testing. Cambridge, MA: National Bureau of Economic Research, wrzesień 2013. http://dx.doi.org/10.3386/w19397.
Pełny tekst źródłaFoley, Brian Thomas, Thomas Kenneth Leitner, Cristian Apetrei, Beatrice Hahn, Ilene Mizrachi, James Mullins, Andrew Rambaut, Steven Wolinsky i Bette Tina Marie Korber. HIV Sequence Compendium 2015. Office of Scientific and Technical Information (OSTI), październik 2015. http://dx.doi.org/10.2172/1222684.
Pełny tekst źródłaKuiken, Carla, Brian Foley, Thomas Leitner, Christian Apetrei, Beatrice Hahn, Ilene Mizrachi, James Mullins, Andrew Rambaut, Steven Wolinsky i Bette Korber. HIV Sequence Compendium 2010. Office of Scientific and Technical Information (OSTI), grudzień 2010. http://dx.doi.org/10.2172/1223877.
Pełny tekst źródłaKuiken, Carla, Brian Foley, Eric Freed, Beatrice Hahn, Preston Marx, Francine McCutchan, John Mellors, Steven Wolinsky i Bette Korber. HIV sequence compendium 2002. Office of Scientific and Technical Information (OSTI), grudzień 2002. http://dx.doi.org/10.2172/1184349.
Pełny tekst źródłaKuiken, Carla, i Brian Foley. HIV Sequence Compendium 2000. Office of Scientific and Technical Information (OSTI), styczeń 2000. http://dx.doi.org/10.2172/1186021.
Pełny tekst źródła